Alphabet Inc.'s (NASDAQ: GOOG) Google Cloud introduced two new AI-powered tools that hold the potential to revolutionize the drug development process for biotech and pharmaceutical companies.
With the aim of expediting the discovery and advancement of new drugs, these tools, Target and Lead Identification Suite and Multiomics Suite, leverage artificial intelligence to streamline crucial stages of drug development.
By harnessing the power of AI, Google Cloud intends to significantly reduce the time and cost associated with bringing new drugs to market.
Google Cloud's Target and Lead Identification Suite
At the Bio-IT World Conference, Google Cloud unveiled the Target and Lead Identification Suite, designed to assist biotech and pharmaceutical companies in predicting and comprehending protein structures—an essential aspect …